PT  - JOURNAL ARTICLE
AU  - Umesh Dashora
AU  - Robert Gregory
AU  - Peter Winocour
AU  - Ketan Dhatariya
AU  - Susannah Rowles
AU  - Andrew Macklin
AU  - Gerry Rayman
AU  - Dinesh Nagi
AU  - Katie Whitehead
AU  - Hannah Beba
AU  - Parijat De
AU  - Dipesh C Patel
AU  - on behalf of the ABCD executive committee and Diabetes UK
TI  - Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)
AID  - 10.7861/clinmed.2021-0045
DP  - 2021 May 01
TA  - Clinical Medicine
PG  - 204--210
VI  - 21
IP  - 3
4099  - http://www.rcpjournals.org/content/21/3/204.short
4100  - http://www.rcpjournals.org/content/21/3/204.full
SO  - Clin Med2021 May 01; 21
AB  - Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment of type 2 diabetes (T2D), no longer reserved for use by specialists in diabetes. They are being used increasingly for their cardiac and renal benefits by primary care, cardiology and renal teams for indications in parallel with diabetes care as part of holistic management. This guidance provides essential information on SGLT therapy, including the main advantages and the important risks of which healthcare professionals should be aware.